147 related articles for article (PubMed ID: 10881697)
1. Initiation of humoral and cellular immune responses in patients with refractory Hodgkin's disease by treatment with an anti-CD16/CD30 bispecific antibody.
Renner C; Hartmann F; Jung W; Deisting C; Juwana M; Pfreundschuh M
Cancer Immunol Immunother; 2000 Jun; 49(3):173-80. PubMed ID: 10881697
[TBL] [Abstract][Full Text] [Related]
2. A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo.
Hombach A; Jung W; Pohl C; Renner C; Sahin U; Schmits R; Wolf J; Kapp U; Diehl V; Pfreundschuh M
Int J Cancer; 1993 Nov; 55(5):830-6. PubMed ID: 8244580
[TBL] [Abstract][Full Text] [Related]
3. Immune recruitment by bispecific antibodies for the treatment of Hodgkin disease.
da Costa L; Renner C; Hartmann F; Pfreundschuh M
Cancer Chemother Pharmacol; 2000; 46 Suppl():S33-6. PubMed ID: 10950145
[TBL] [Abstract][Full Text] [Related]
4. Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody.
Hartmann F; Renner C; Jung W; Deisting C; Juwana M; Eichentopf B; Kloft M; Pfreundschuh M
Blood; 1997 Mar; 89(6):2042-7. PubMed ID: 9058726
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD16/CD30 bispecific antibodies as possible treatment for refractory Hodgkin's disease.
Hartmann F; Renner C; Jung W; Pfreundschuh M
Leuk Lymphoma; 1998 Oct; 31(3-4):385-92. PubMed ID: 9869203
[TBL] [Abstract][Full Text] [Related]
6. Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody.
Renner C; Hartmann F; Pfreundschuh M
Cancer Immunol Immunother; 1997; 45(3-4):184-6. PubMed ID: 9435869
[TBL] [Abstract][Full Text] [Related]
7. Treatment of heterotransplanted Hodgkin's tumors in SCID mice by a combination of human NK or T cells and bispecific antibodies.
Renner C; Pfreundschuh M
J Hematother; 1995 Oct; 4(5):447-51. PubMed ID: 8581383
[TBL] [Abstract][Full Text] [Related]
8. Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines.
Hartmann F; Renner C; Jung W; da Costa L; Tembrink S; Held G; Sek A; König J; Bauer S; Kloft M; Pfreundschuh M
Clin Cancer Res; 2001 Jul; 7(7):1873-81. PubMed ID: 11448899
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma.
Borchmann P; Schnell R; Fuss I; Manzke O; Davis T; Lewis LD; Behnke D; Wickenhauser C; Schiller P; Diehl V; Engert A
Blood; 2002 Nov; 100(9):3101-7. PubMed ID: 12384405
[TBL] [Abstract][Full Text] [Related]
10. A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells.
Reusch U; Burkhardt C; Fucek I; Le Gall F; Le Gall M; Hoffmann K; Knackmuss SH; Kiprijanov S; Little M; Zhukovsky EA
MAbs; 2014; 6(3):728-39. PubMed ID: 24670809
[TBL] [Abstract][Full Text] [Related]
11. Targeting properties of an anti-CD16/anti-CD30 bispecific antibody in an in vivo system.
Renner C; Stehle I; Lee FT; Hall C; Catimel B; Nice EC; Mountain A; Rigopoulos A; Brechbiel MW; Pfreundschuh M; Scott AM
Cancer Immunol Immunother; 2001 Apr; 50(2):102-8. PubMed ID: 11401024
[TBL] [Abstract][Full Text] [Related]
12. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells.
Renner C; Jung W; Sahin U; Denfeld R; Pohl C; Trümper L; Hartmann F; Diehl V; van Lier R; Pfreundschuh M
Science; 1994 May; 264(5160):833-5. PubMed ID: 8171337
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-12 increases bispecific-antibody-mediated natural killer cell cytotoxicity against human tumors.
Sahin U; Kraft-Bauer S; Ohnesorge S; Pfreundschuh M; Renner C
Cancer Immunol Immunother; 1996 Jan; 42(1):9-14. PubMed ID: 8625370
[TBL] [Abstract][Full Text] [Related]
14. Cure of disseminated xenografted human Hodgkin's tumors by bispecific monoclonal antibodies and human T cells: the role of human T-cell subsets in a preclinical model.
Renner C; Bauer S; Sahin U; Jung W; van Lier R; Jacobs G; Held G; Pfreundschuh M
Blood; 1996 Apr; 87(7):2930-7. PubMed ID: 8639913
[TBL] [Abstract][Full Text] [Related]
15. Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment.
Clark JI; Alpaugh RK; von Mehren M; Schultz J; Gralow JR; Cheever MA; Ring DB; Weiner LM
Cancer Immunol Immunother; 1997 Jul; 44(5):265-72. PubMed ID: 9247561
[TBL] [Abstract][Full Text] [Related]
16. A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin's tumors.
Arndt MA; Krauss J; Kipriyanov SM; Pfreundschuh M; Little M
Blood; 1999 Oct; 94(8):2562-8. PubMed ID: 10515858
[TBL] [Abstract][Full Text] [Related]
17. Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.
Weiner LM; Clark JI; Ring DB; Alpaugh RK
J Hematother; 1995 Oct; 4(5):453-6. PubMed ID: 8581384
[TBL] [Abstract][Full Text] [Related]
18. Anti-idiotype vaccine against Hodgkin's lymphoma: induction of B- and T-cell immunity across species barriers against CD30 antigen by murine monoclonal internal image antibodies.
Pohl C; Renner C; Schwonzen M; Sieber M; Lorenz P; Pfreundschuh M; Diehl V
Int J Cancer; 1992 Apr; 50(6):958-67. PubMed ID: 1313400
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.
Weiner LM; Clark JI; Davey M; Li WS; Garcia de Palazzo I; Ring DB; Alpaugh RK
Cancer Res; 1995 Oct; 55(20):4586-93. PubMed ID: 7553634
[TBL] [Abstract][Full Text] [Related]
20. Bispecific antibody-mediated destruction of Hodgkin's lymphoma cells.
Sundarapandiyan K; Keler T; Behnke D; Engert A; Barth S; Matthey B; Deo YM; Graziano RF
J Immunol Methods; 2001 Feb; 248(1-2):113-23. PubMed ID: 11223073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
